Hibsago is viewed as a potential “functional cure” for chronic infections and an important part of the British drugmaker’s ...

Shortly after winning a clearance in the skin disease dermatomyositis, brepocitinib posted results suggesting it might also ...

Early CDMO engagement can be valuable, particularly when it helps development teams understand technical requirements, ...

Roche is paying Hansoh $400 million up front in a broad deal involving several ADCs. Elsewhere, another top investor formed a ...

The acquisition gives the German company a promising blood disorder medicine that passed a Phase 2 test and could threaten a ...

A revamped regulatory framework may give investors less of a “guessing game” as they weigh chances for drug approvals, one ...

The offering will support a trio of medicines in or nearing clinical testing, as well as earlier research into RNAi ...

Fresh off a $150 million IPO, Tom Miller spoke to BioPharma Dive about the roadshow process and how he sees AI’s role in drug ...

The latest installment in BioPharma Dive’s data visualization-focused series includes a look at Moderna’s meteoric rise in 2026 and a sudden deal surge from Roche.

The Series A round, which was led by RA Capital, will help fund the development of two genetic medicines designed to treat an ...

Months after the FDA rejected its treatment for a rare light-sensitivity disease, the biotech claimed success in a Phase 3 ...

Armed Cell Therapeutics, chaired by former Galapagos CEO Paul Stoffels, has assumed control of cell therapies the company — now known as Lakefront Biotherapeutics — divested in a strategic overhaul.